There is a causal relationship between hepatitis B virus infection and hepatocellular carcinoma (Beasley et al., 1981; . Nonetheless, HBV replication may be weak or absent, since serum from patients with HCC contains low or undetectable levels of HBV DNA (Lieberman et al., 1983; Fowler et al., 1984; Song et al., 1984) . Interferon inhibits HBV replication in hepatitis patients (Scullard et al., 1981; Thomas & Bassendine, 1980; Omata et al., 1985) 
There is a causal relationship between hepatitis B virus infection and hepatocellular carcinoma (Beasley et al., 1981; . Nonetheless, HBV replication may be weak or absent, since serum from patients with HCC contains low or undetectable levels of HBV DNA (Lieberman et al., 1983; Fowler et al., 1984; Song et al., 1984) . Interferon inhibits HBV replication in hepatitis patients (Scullard et al., 1981; Thomas & Bassendine, 1980; Omata et al., 1985) , but its effect on patients with HCC has so far not been reported. This report deals with HBV DNA and DNAp in HCC patients treated with rIFN-A or adriamycin . By testing serial specimens collected over weeks or months, we have been able to show that free HBV DNA sequences may appear intermittently in some patients during adriamycin or rIFN-A treatment. In other patients, serum HBV DNA disappeared during rIFN-A treatment.
Materials and methods
Preparation of HBV DNA probes from plasma A standard procedure (Weller et al., 1982) September 1985; and in revised form, 6 February 1986 modified with a DNAse digestion step in order to eliminate human DNA. Plasma specimens rejected by the blood bank because of HBsAg positivity were used as the source of HBV DNA. Each specimen (-150 ml) was centrifuged at 2000g (1 hr, 4°C). Six 25ml portions were layered over 10ml 30% sucrose cushions and centrifuged (70,000g, 17 h, 4°C) . The pellets were suspended in 2 ml 0.1 M sodium acetate-0.005 M Mg acetate, pH 5, and 40 il pancreatic DNAse (lmgml-1 in 0.15M NaCl-50% glycerol) was added. After 20 min at 37°C, 0.1 ml 0.2 M EDTA, pH 7, was added and the mixture was layered over 30 ml 30% sucrose and ultracentrifuged as before. (An optional [3H]-labelling step was carried out: the pellet was dissolved in Nonidet P 40-mercaptoethanol-Tris-saline and 100I d buffer salts solution containing 10 uCi [3H]dCTP (specific activity 20 Ci mmol-1), dATP, dGTP and dTTP was added. After 2 h at 37°C, 200 ul 0.2 M EDTA was added; the mixture was layered over 4.2 ml 30% sucrose made up in Tris-EDTA-mercaptoethanol-albumin-saline (Lin et al., 1983) and centrifuged (190, OOOg, 4 h, 4°C) (Howley et al., 1979) . Washing was carried out exactly according to Berninger et al. (1982) .
Radioautography was performed with Kodak XRP-1 film and intensifying screens, at -70°C. By nick-translating the HBV DNA with the highest specific activity dCTP available, the dot hybridisation test was made more sensitive than the DNAp assay (Lin et al., 1984 (Helling et al., 1974) . Blots were prepared according to a standard procedure (Maniatis et al., 1982) on to nitrocellulose or nylon membranes. The samples analysed by Southern blotting were either HBV DNA preparations that were employed (in other experiments) for nick translation, or serum extracts that were prepared by the proteinase K method specified above and concentrated by means of ethanol precipitation. Hind III digests of lambda DNA were co-electrophoresed in side lanes. The conditions of hybridisation and washing were identical to those employed in dot hybridisation.
Other methods Nucleic acids that were transferred to nylon membranes ('Hybond-N', Amersham International) were fixed by ultraviolet irradiation. Removal of probe from the nylon sheets was accomplished by two cycles of immersion in 0.4 M NaOH (45°C, 30 min) followed by incubation in a solution composed of 0.2M Tris-HCl (pH 7.5), 0.1% sodium dodecyl sulfate, 0.015M NaCl-0.0015M sodium citrate (45°C, 30 min). Complete removal of radioactivity by this procedure was checked by radioautography of the stripped membranes.
DNAp was assayed by the phosphonoformate inhibition method; the cut-off point for serum negative for HBsAg, HBsAb and HBcAb was 15 nU I1 (Lin et al., 1984) . The serological tests for HBV markers are given in the same paper.
Patients
All patients with histologically proven HCC were randomised to receive adriamycin or recombinant leukocyte A interferon (rIFN-A) (Roche) when the following criteria were fulfilled: (a) the HCCs were inoperable as proven by hepatic arteriogram and/or CT scan, (b) patient's age was less than 75 yrs, (c) the patients' performance status were over 60% using the Karnovsky scale (i.e. they were able to take care of most of their daily activities), (d) the serum bilirubin levels were below lOO pmoll-', (e) the patients had no cardiac complaints and normal electrocardiograms and (f) informed consent was obtained.
Patients on adriamycin were given an initial dose of 60mgm 2 intra,venously. If this dose was well tolerated, the dose was stepped up to 75mg m-2 once every three weeks. Patients receiving rIFN-A were randomised on two regimes: (a) 9-18 x 106IUm-2 intramuscularly daily and (b) 25-50 x 106IUm-2 intramuscularly thrice weekly. The general clinical status of the patients on the different regimes were comparable, and the clinical tolerance of the patients to rIFN-A, which has been noted will be detailed elsewhere (Lai et al., in preparation) . The HBV DNA findings of the first 31 patients are presented below.
Results Table I presents the findings together with the treatment and serological data. Fifteen patients were studied for 1-3 weeks (1-2 specimens per case); six patients were followed for 5-10 weeks (3-7 specimens per case) and 10 patients were followed for 14-42 weeks (6-22 specimens per case). Seven cases showed HBV DNA at some time during the periods of observation. There was no statistically significant association between the frequency of HBV DNA positivity and either treatment. All 31 cases were HBsAg positive. Of the 12 HBeAgpositive patients, only two were HBV DNA positive. Five of the 18 HBeAb-positive cases were HBV DNA positive.
The possibility that interference from traces of human DNA in the HBV DNA probes could have produced the findings was excluded. Figure 1 shows Figure 4 shows blots of serum samples in cases treated with adriamycin. HBV DNA appeared intermittently in case 4. It was first detected at week 4 (with an elevated DNAp) and then from week 7 onwards with increasing intensity.
Case 5 was treated with adriamycin for 24 weeks and switched to rIFN-A at 27 weeks. Her serum HBV DNA diminished over the ensuing weeks. Case 6 shows the presence of HBV DNA after 12 weeks of adriamycin treatment. Case 7 was strongly positive at weeks 0-4; he died during week 5.
The Southern blots showed that with the exception of specimens from case 3, the sequences hybridised to HBV DNA were present in fragments approximately 2.2 to 3.2kbp in length. Similar size distributions have been observed in DNA extracted from purified HBV particles (Landers et al., 1977) . Moreover, similar size distributions were observed in HBV DNA specimens that had been extracted from DNAse-treated human plasma (Figure 1, C (Figure 4, right) showed the highest levels of DNAp activity, consistent with its high HBV DNA concentration. Cases 3-5 had mildly raised DNAp activity in most specimens that were positive for HBV DNA. There was general agreement between the HBV DNA tests and DNAp activities in these 4 patients, proving that infective HBV was present in their serum. The failure to find DNAp levels in cases 1 and 2 was not surprising, in view of the greater sensitivity of the hybridisation technique. Table II summarizes the data on serum transaminases and HBeAg and HBeAb status. AST was higher than ALT in these patients, but correlation with the presence or absence of serum HBV DNA was poor. HBeAg and HBeAb were followed throughout the courses of treatment. Seroconversion from HBeAb to HBeAg was found only in one patient (case 4, week 13) when his serum HBV DNA was very strongly positive. (Song et al., 1984) . In our 7 positive cases 2 were HBeAgpositive and 5 were HBeAb-positive. In the South African study, the majority of the HBV DNA positive cases were HBeAg-positive (14/20), 5 were HBeAb positive and one was not tested for HBeAb.
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HBeAb-positive HCC patients are, then, like HBeAb-positive chronic hepatitis patients in that they often show HBV DNA in serum (Lieberman et al., 1983) .
Comments on the effects of treatment are necessarily tentative because of the small number of cases. Treatment with adriamycin in cases 4-7 did not prevent HBV replication. Since one effect of adriamycin is to inhibit RNA-dependent DNA synthesis (Bosman & Kessel, 1971) 
